Potentia Pharmaceuticals

LOUISVILLE, Kentucky - -- Alcon takes over development of POT-4 as a treatment for patients with age-related macular degeneration -- Deal provides path for Alcon to acquire Potentia Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.